84 research outputs found
Two Dimensions of Nutritional Value: Nutri-Score and NOVA
Front-of-pack labels can improve the ability of consumers to identify which foods are healthier, making them a useful public health tool. Nutri-Score is a front-of-pack labelling system adopted by several European countries. This system ranks foods according to their nutritional quality, but does not consider other dimensions such as the degree of food processing. The aim of this study is to compare the nutritional quality (as assessed by Nutri-Score) and the ultra-processing (as assessed by the NOVA classification) of foods in the Open Food Facts database. A simple correspondence analysis was carried out to study the relationship between the two systems. Ultra-processed foods (NOVA 4) were found in all Nutri-Score categories, ranging from 26.08% in nutritional category A, 51.48% in category B, 59.09% in category C, 67.39% in category D to up to 83.69% in nutritional category E. Given the negative effect that the consumption of ultra-processed foods has on different aspects of health, front-of-pack labelling with Nutri-Score should at least be accompanied by complementary labelling indicating the level of processing, such as the NOVA classification
The prognosis of patients hospitalized with a first episode of heart failure, validation of two scores: PREDICE and AHEAD.
Purpose: Heart failure (HF) is a chronic, frequent and disabling condition but with a
modifiable course and a large potential for improving. The aim of this study was to validate
the two available clinical prediction rules for mortality at one year in patients with primo-
hospitalization for decompensated HF: PREDICE and AHEAD. The secondary aim was to
evaluate in our setting the changes in the clinical pattern of HF in the last decade in patients
hospitalized for a first episode of the disease.
Patients and methods: A prospective multicenter cohort study, which included 180
patients hospitalized with “de novo” HF was conducted to validate the PREDICE score.
Calibration and discrimination measurements were calculated for the PREDICE model and
the PREDICE score (using the validation cohort of the PREDICE) and the AHEAD score
(using both the development and the validation cohort of the PREDICE).
Results: For the PREDICE models, the area under the curve (AUC) was 0.68 (95% confidence
interval [CI]: 0.57–0.79) and the calibration slope 0.65 (95% CI: 0.21–1.20). For the PREDICE
score AUC was 0.59 (95% CI: 0.47–0.71) and slope 0.42 (95% CI: −0.20–1.17). For the AHEAD
score the AUC was 0.68 (95% CI: 0.62–0.73) and slope 1.38 (95% CI: 0.62–0.73) when used the
development cohort of PREDICE and the AUC was 0.58 (95% CI: 0.49–0.67), and slope 0.68
(95% CI: −0.06 to 1.47) when used its validation cohort.
Conclusion: The present study shows that the two risk scores available for patients with
primo-hospitalization for decompensated HF (PREDICE and AHEAD) are not currently
valid for predicting mortality at one-year. In our setting the clinical spectrum of hospitalized
patients with new-onset HF has been modified over time. The study underscores the need to
validate the prognostic models before clinical implementation.Ministerio de Sanidad PI070945
The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge.
In 1981, in Spain, the ingestion of an oil fraudulently sold as olive oil caused an outbreak of a previously unrecorded condition, later known as toxic oil syndrome (TOS), clinically characterized by intense incapacitating myalgias, marked peripheral eosinophilia, and pulmonary infiltrates. Of the 20,000 persons affected, approximately 300 died shortly after the onset of the disease and a larger number developed chronic disease. For more than 15 years, a scientific committee supported by the World Health Organization's Regional Office for Europe and by the Institute of Health Carlos III in Madrid has guided investigation intended to identify the causal agent(s), to assess toxicity and mode of action, to establish the pathogenesis of the disease, and to detect late consequences. This report summarizes advances in research on this front. No late mortality excess has been detected. Among survivors, the prevalence of some chronic conditions (e.g., sclerodermia, neurologic changes) is high. Attempts to reproduce the condition in laboratory animals have been unsuccessful, and no condition similar to TOS has been reported in the scientific literature. Laboratory findings suggest an autoimmune mechanism for TOS, such as high levels of seric soluble interleukin-2 receptor. Epidemiologic studies integrated with chemical analyses of case-related oils have shown that the disease is strongly associated with the consumption of oils containing fatty acid esters of 3-(N-phenylamino)-1,2-propanediol (PAP). These chemicals have also been found in oils synthesized under conditions simulating those hypothesized to have occurred when the toxic oil was produced in 1981. Whether PAP esters are simply markers of toxicity of oils or have the capability to induce the disease remains to be elucidated
Role of biological and non biological factors in congestive heart failure mortality: PREDICE-SCORE: A clinical prediction rule
Background: Congestive heart failure (HF) is a chronic, frequent and disabling condition but with a modifiable course and a large potential for improving. The aim of this project was to develop a clinical prediction model of biological and non biological factors in patients with first diagnosis of HF that facilitates the risk-stratification and decision-making process at the point of care. Methods and Results: Historical cohort analysis of 600 patients attended at three tertiary hospitals and diagnosed of a first episode of HF according Framingham criteria. There were followed 1 year. We analyzed sociodemographic, clinical and laboratory data with potential prognostic value. The modelling process concluded into a logistic regression multivariable analysis and a predictive rule: PREDICE SCORE. Age, dependency for daily basic activities, creatinine clearance, sodium levels at admission and systolic dysfunction diagnosis (HF with left ventricular ejection fraction < 40%) were the selected variables. The model showed a c-statistic of 0.763. PREDICE Score, has range of 22 points to stratifications of 1-year mortality. Conclusions: The follow-up of 600 patients hospitalized by a first episode of congestive HF, allowed us to obtain a predictive 1 year mortality model from the combination of demographic data, routine biochemistry and easy handling social and functional variables at the point of care. The variables included were non-invasive, undemanding to collect, and widely available. It allows for risk stratification and therapeutical targeting and may help in the clinical decisions process in a sustainable way
Level of blood pressure control in a hypertensive population when measurements are performed outside the clinical setting
Background: To determine whether the number of optimally controlled hypertensive patients
is higher using self-measurement of blood pressure at home and ambulatory monitoring,
compared to using conventional blood pressure measurements at the doctor’s office.
Method: An observational, cross-sectional, multicentre, descriptive study of a random sample
of 237 primary health care patients, known to be hypertensive, from Badajoz (Spain). Blood
pressure was measured at the doctor’s office and by self-measurement at home. Those patients
showing good control by self-measurement were subjected to 24-hour ambulatory monitoring.
Optimal control was understood as blood pressure < 140/90 mm Hg when measured at the
doctor’s office, and < 135/85 mm Hg when self-measured at home and by daytime ambulatory
monitoring.
Results: Mean systolic/diastolic measurements at the doctor’s office and by self-measurement
were 145.6/83.9 and 134.0/78.7 mm Hg, respectively (p < 0.000). In the population optimally
controlled by self-measurement and who subsequently received ambulatory monitoring, the
mean blood pressure was 121.8/73.4 and 125.6/76.2 mm Hg, respectively (p = 0.002; p < 0.000).
When measured at the doctor’s office blood pressure was controlled in about 29.5% (95% CI
23.7-35.3%) of patients, in 38% when self-measured (95% CI 31.4-44.2%; p < 0.000), and
in 24.5% when it was confirmed through ambulatory monitoring (95% CI 15.4-33.6%).
Sensitivity and positive predictive values of the office measurements for the detection of patients
who were well-controlled by self-measurement were 50% and 64.3%, respectively, and
53.4% and 73.8% as regards ambulatory monitoring. Conclusions: A higher level of control is achieved with self-measurement at home not confirmed
by ambulatory monitoring. Therefore, the white coat effect does not seem to influence
the percentage of well-controlled patients detected at the doctor’s office. Office blood pressure
does not appear to be useful in distinguishing which individual patients are optimally controlled
IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality
Cardiovascular complications are the most important cause
of death in patients on dialysis with end-stage renal disease.
Antibodies reacting with b-glycoprotein I seem to play a
pathogenic role in antiphospholipid syndrome and stroke
and are involved in the origin of atherosclerosis. Here
we evaluated the presence of anticardiolipin and anti-bglycoprotein
I antibodies together with other vascular
risk factors and their relationship with mortality and
cardiovascular morbidity in a cohort of 124 hemodialysis
patients prospectively followed for 2 years. Of these,
41 patients were significantly positive for IgA anti-bglycoprotein
I, and the remaining had normal values. At 24
months, overall and cardiovascular mortality and thrombotic
events were all significantly higher in patients with high antib-
glycoprotein I antibodies. Multivariate analysis using Cox
regression modeling found that age, hypoalbuminemia, use
of dialysis catheters, and IgA b-glycoprotein I antibodies were
independent risk factors for death. Thus, IgA antibodies to
b-glycoprotein I are detrimental to the clinical outcome of
hemodialysis patients.Fundacio´n Mutua Madrilena (2008-090), and from Fondo de
Investigaciones Sanitarias (PS09-02023
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
Background: The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. Methods: Between April 24 and 30, 2021, 676 adults primed with ChAdOx1-S were enrolled in five hospitals in Spain, and randomised to receive BNT162b2 as second dose (interventional group [IG]) or no vaccine (control group [CG]). Individuals from CG received BNT162b2 as second dose and also on day 28, as planned based on favourable results on day 14. Humoral immunogenicity, measured by immunoassay for SARS-CoV-2 receptor binding domain (RBD), antibody functionality using pseudovirus neutralisation assays for the reference (G614), Alpha, Beta, Delta, and Omicron variants, as well as cellular immune response using interferon-γ and IL-2 immunoassays were assessed at day 28 after BNT162b2 in both groups, at day 90 (planned only in the interventional group) and at day 180 (laboratory data cut-off on Nov 19, 2021). This study was registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739). Findings: In this secondary analysis, 664 individuals (441 from IG and 223 from CG) were included. At day 28 post vaccine, geometric mean titres (GMT) of RBD antibodies were 5616·91 BAU/mL (95% CI 5296·49-5956·71) in the IG and 7298·22 BAU/mL (6739·41-7903·37) in the CG (p 1:100 at day 180 (19% and 22%, respectively). Interpretation: Titres of RBD antibodies decay over time, similar to homologous regimes. Our findings suggested that delaying administration of the second dose did not have a detrimental effect after vaccination and may have improved the response obtained. Lower neutralisation was observed against Omicron and Beta variants at day 180.Funded by Instituto de Salud Carlos III (ISCIII). AMB, AJC, JO, and JF are members of the VACCELERATE (European Corona Vaccine Trial Accelerator Platform) Network, which aims to facilitate and accelerate the design and implementation of COVID-19 phase 2 and 3 vaccine trials. JO is a member of the INsTRuCT (Innovative Training in Myeloid Regulatory Cell Therapy) Consortium, a network of European scientists from academia and industry focused on developing innovative immunotherapies. This work is funded by Instituto de Salud Carlos III, a Spanish public body assigned to the Ministry of Science and Innovation that manages and promotes public clinical research related to public health. The Spanish Clinical Trials Platform is a public network funded by the Instituto de Salud Carlos III (grant numbers PTC20/00018 and PT17/0017), the State Plan for Research, Development, and Innovation 2013−16, the State Plan for Scientific and Technical Research and Innovation 2017−20, and the Subdirectorate General for Evaluation and Promotion of Research, Instituto de Salud Carlos III, cofinanced with FEDER funds. CombiVacS was designed under the umbrella of the VACCELERATE project. VACCELER ATE and INsTRuCT received funding from the EU’s Horizon 2020 Research and Innovation Programme (grant agreement numbers 101037867 and 860003). The Instituto de Salud Carlos III is the Spanish partner in the VACCELERATE project. This work is partially funded by Institute of Health Carlos III (Instituto de Salud Carlos III − ISCIII −), (grants PI19CIII/00004 to JA and PI21CIII/00025 to MPO and JGP), and COVID-19 FUND (grants COV20/00679 and COV20/00072 to MPO and JA) and CIBERINFEC, co-financed by the European Regional Development Fund (FEDER) “A way to make Europe”. The authors thank all trial participants, the international data safety monitoring board (Appendix 1 p 23), and the trial steering committee (Appendix 1 pp 24−25). The authors thank Esther Prieto for editorial assistance and writing support (employed by Hospital Universitario La Paz; funded by the Instituto de Salud Carlos III, grant number PCT20/00018) and María Castillo-de la Osa (PEJ2018-004557-A) for excellent technical assistance.S
Interaction between cardiovascular risk factors and body mass index and 10-year incidence of cardiovascular disease, cancer death, and overall mortality
The effect of above-normal body mass index (BMI) on health outcomes is controversial because it is difficult to distinguish from the effect due to BMI-associated cardiovascular risk factors. The objective was to analyze the impact on 10-year incidence of cardiovascular disease, cancer deaths and overall mortality of the interaction between cardiovascular risk factors and BMI. We conducted a pooled analysis of individual data from 12 Spanish population cohorts with 10-year follow-up. Participants had no previous history of cardiovascular diseases and were 35-79years old at basal examination. Body mass index was measured at baseline being the outcome measures ten-year cardiovascular disease, cancer and overall mortality. Multivariable analyses were adjusted for potential confounders, considering the significant interactions with cardiovascular risk factors. We included 54,446 individuals (46.5% with overweight and 27.8% with obesity). After considering the significant interactions, the 10-year risk of cardiovascular disease was significantly increased in women with overweight and obesity [Hazard Ratio=2.34 (95% confidence interval: 1.19-4.61) and 5.65 (1.54-20.73), respectively]. Overweight and obesity significantly increased the risk of cancer death in women [3.98 (1.53-10.37) and 11.61 (1.93-69.72)]. Finally, obese men had an increased risk of cancer death and overall mortality [1.62 (1.03-2.54) and 1.34 (1.01-1.76), respectively]. In conclusion, overweight and obesity significantly increased the risk of cancer death and of fatal and non-fatal cardiovascular disease in women; whereas obese men had a significantly higher risk of death for all causes and for cancer. Cardiovascular risk factors may act as effect modifiers in these associations
Conexión inteligente para la gestión turística desde el aula al destino (CIGTAD – II)
Para reducir la brecha digital existente en la sociedad actual es necesario situar la innovación en el núcleo de la toma de decisiones. Este proyecto camina hacia la plena inclusión de todos los colectivos de la comunidad universitaria en el uso de las nuevas tecnologías, y gracias a ellas, poder generar una mayor conciencia social y medioambiental. Desarrollaremos soluciones para la mejora de la accesibilidad a la información que se genera, tanto formal como informal, para los grupos implicados y en cuyos contenidos se introducirá la conceptualización de los ODS y su implicación en sectores tan importantes como el Comercio y el Turismo. Se trabajará con tecnología actual y futura de los destinos turísticos, lo que mejorará, a su vez, la empleabilidad de los egresados en la facultad.
El proyecto impulsa la implementación de las tecnologías que se están utilizando en los planes estratégicos de Destinos Turísticos Inteligentes. De este modo, los estudiantes del Grado en Turismo y el Doble Grado en Turismo y Comercio, así como del Máster en Planificación y Gestión de Destinos Turísticos podrán experimentar la inmersión en el uso de este tipo de herramientas.
El proyecto estará dividido en 3 fases como son: el análisis, el desarrollo de contenidos y la implementación de las herramientas en el que participarán diferentes colectivos tales como PDI, PAS y Estudiantes de diferentes niveles y Alumni de la Facultad de Comercio y Turismo, así como la participación de una trabajadora social experta en trabajar con colectivos juveniles.
El proyecto está alineado para trabajar por mejorar la sostenibilidad de la facultad e incrementar el nivel de compromiso de los colectivos con los objetivos de la Agenda 2030
Stability of SARS-CoV-2 spike antigens against mutations
Modern health care needs preventive vaccines and therapeutic treatments with stability against pathogen mutations to cope with current and future viral infections. At the beginning of the COVID-19 pandemic, our analytic and predictive tool identified a set of eight short SARS-CoV-2 S-spike protein epitopes that had the potential to persistently avoid mutation. Here a combination of genetic, Systems Biology and protein structure analyses confirm the stability of our identified epitopes against viral mutations. Remarkably, this research spans the whole period of the pandemic, during which 93.9% of the eight peptides remained invariable in the globally predominant 43 circulating variants, including Omicron. Likewise, the selected epitopes are conserved in 97% of all 1,514 known SARS-CoV-2 lineages. Finally, experimental analyses performed with these short peptides showed their specific immunoreactivity. This work opens a new perspective on the design of next-generation vaccines and antibody therapies that will remain reliable against future pathogen mutations.Dr. Lozano-Perez acknowledges the European Commission ERDF/FEDER Operational Program 'Murcia' CCI No. 2007ES161PO001 (Project No. 14-20/20). Miodrag Grbic acknowledges support from the NSERC Discovery grant (Canada). This work also has received funding from the Department of Education of the Basque Government via the Consolidated Research Group MATH MODE (IT1456-22). Besides, Ildefonso Martinez De la Fuente and Iker Malaina were supported by the UPV/EHU and Basque Center of Applied Mathematics, grant US21/27N
- …